NCT02101034View on ClinicalTrials.gov

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 17, 2014

Primary Completion Date

June 8, 2020

Study Completion Date

November 10, 2023

Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
BIOLOGICAL

Cetuximab

DRUG

PD 0332991

Trial Locations (5)

14642

University of Rochester Medical Center, Rochester

30322

Winship Cancer Institute of Emory University, Atlanta

48109

University of Michigan Health System, Ann Arbor

63110

Washington University School of Medicine, St Louis

66205

University of Kansas, Westwood

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02101034 - PD 0332991 and Cetuximab in Patients With Incurable SCCHN | Biotech Hunter | Biotech Hunter